Physical and Actuarial Escape Velocities

The escape velocity cusp is closer than you might guess. Since we are already so long lived, even a 30% increase in healthy life span will give the first beneficiaries of rejuvenation therapies another 20 years—an eternity in science—to benefit from second-generation therapies that would give another 30%, and so on ad infinitum. Thus, if first-generation rejuvenation therapies were universally available and this progress in developing rejuvenation therapy could be indefinitely maintained, these advances would put us beyond AEV. Universal availability might be thought economically and sociopolitically implausible (though that conclusion may be premature, as I will summarise below), so it's worth considering the same question in terms of life-span potential (the life span of the luckiest people). Figure 1 again illustrates this: those who get first-generation therapies only just in time will in fact be unlikely to live more than 20–30 years more than their parents, because they will spend many frail years with a short remaining life expectancy (i.e., a high risk of imminent death), whereas those only a little younger will never get that frail and will spend rather few years even in biological middle age. Quantitatively, what this means is that if a 10% per year decline of mortality rates at all ages is achieved and sustained indefinitely, then the first 1000-year-old is probably only 5–10 years younger than the first 150-year-old.


Folksonomies: longevity life-extension

/health and fitness/therapy (0.387572)
/health and fitness/aging (0.200655)
/society/work/retirement (0.165853)

first-generation rejuvenation therapies (0.960373 (positive:0.504242)), escape velocity cusp (0.821374 (neutral:0.000000)), Actuarial Escape Velocities (0.803974 (neutral:0.000000)), life span (0.696781 (positive:0.326108)), healthy life span (0.690604 (positive:0.369835)), short remaining life (0.589478 (negative:-0.527703)), biological middle age (0.577560 (negative:-0.697574)), first-generation therapies (0.522142 (negative:-0.423408)), second-generation therapies (0.496297 (positive:0.369835)), rejuvenation therapy (0.457701 (positive:0.504242)), ad infinitum (0.399334 (negative:-0.235813)), luckiest people (0.389862 (positive:0.282381)), years—an eternity (0.378931 (positive:0.369835)), science—to benefit (0.356278 (positive:0.369835)), imminent death (0.350331 (negative:-0.664396)), mortality rates (0.341985 (neutral:0.000000)), Universal availability (0.338798 (negative:-0.431258)), high risk (0.319619 (negative:-0.664396))

30%:Quantity (0.010000 (neutral:0.000000)), 1000-year:Quantity (0.010000 (neutral:0.000000)), 10 years:Quantity (0.010000 (neutral:0.000000)), 150-year:Quantity (0.010000 (neutral:0.000000)), 20 years:Quantity (0.010000 (neutral:0.000000)), 30 years:Quantity (0.010000 (neutral:0.000000)), 10%:Quantity (0.010000 (neutral:0.000000))

Mortality rate (0.967467): dbpedia | freebase
Demography (0.870803): dbpedia | freebase | opencyc
Middle Ages (0.837356): dbpedia | freebase | opencyc
Life expectancy (0.834254): dbpedia | freebase
Maximum life span (0.753846): dbpedia | freebase
Death (0.733239): dbpedia | freebase | opencyc
Actuarial science (0.723936): dbpedia | freebase
Life table (0.692854): dbpedia | freebase

 Escape Velocity: Why the Prospect of Extreme Human Life Extension Matters Now
Periodicals>Journal Article:  de Grey, Aubrey D. N. J (2004 Jun 15), Escape Velocity: Why the Prospect of Extreme Human Life Extension Matters Now, PLoS Biol. 2004 Jun; 2(6): e187., Retrieved on 2016-03-08
  • Source Material []
  • Folksonomies: life extension geriatrics


    04 MAR 2015


    How to live longer.